

Maelor PLC
05 April 2007

5 April 2007

Maelor plc ('Maelor' or the 'Company')

Pre-Close Statement and Trading update

The Board of Maelor plc (AIM:MLR), the specialist critical care company is pleased to announce that it expects the outcome for the full year to 31st March 2007 to be ahead of current market expectations.

The positive trading highlighted at the Company's Interim Results on 2nd November 2006 has been sustained into the last quarter of the financial year and the Board anticipates a significant reduction in losses for the second half of the financial year. The sales growth of Volplex, a plasma substitute product, the commercialisation of which has been taken in-house, has continued, driven by active promotion and successful tendering for regional contracts. Sales of catheter flushing devices also continue to progress well.

The Company is actively building its specialist critical care portfolio having recently further added to its 'specials' portfolio a fluid and volume replacement product as well as Aquihex, a product that the Company has developed, for use in hospital infection control. In parallel, late stage development of its complementary plasma substitute product, ISOplex, is progressing to schedule with approval still targeted for late 2008.

Commenting on the Company's performance Tim Wright CEO said:

'We are very pleased with the progress that Maelor has made since the strategic review in June 2006. In line with our new strategy the business is now focused, stabilised and well positioned for rapid organic and acquisitive growth. The acquisition of Acorus announced separately today represents a further step in our strategy to establish a significant business in hospital specialist medicine'

- Ends -